Earnings Call · Q2 FY2025·2025-08-01

Q2 25EPS +52.73%·Rev n/aQ1 25EPS -3.07%·Rev n/aQ4 24EPS +7.86%·Rev n/aQ3 24EPS +6.50%·Rev n/a⚠ consensus missing

REGENERON PHARMACEUTICALS, INC. REGN

Ryan Crowe — Senior Vice President, Investor Relations

Leonard S. Schleifer — President and Chief Executive Officer

George D. Yancopoulos — President and Chief Scientific Officer

Marion E. McCourt — Executive Vice President, Commercial

Christopher R. Fenimore — Senior Vice President, Chief Financial Officer

+2.5%1d on move date+4.1% vs SPY3d+4.5%5d+2.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more REGN calls or request research access.

More REGN calls Browse calls Request research access